Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
- Registration Number
- NCT00918450
- Lead Sponsor
- Abbott
- Brief Summary
This is a Phase 2b, open-label, multicenter, global study assessing the safety and efficacy of ABT-263 in subjects with B-cell CLL who have failed at least one prior fludarabine-containing regimen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 150
-
>= 18 yrs of age, have B-cell CLL, failed at least 1 prior fludarabine-containing regimen.
-
Refractory to 1 fludarabine-containing regimen is defined as failure to achieve at least PR to the last fludarabine-containing regimen received, or disease progression while receiving the last fludarabine-containing regimen, or disease progression in responders (i.e., achieved a PR or CR) within 6 mos of the last cycle of the last fludarabine-containing regimen received (e.g., fludarabine monotherapy, FR, or FC) or in responders (i.e., achieved a PR or CR ) within 24 mos of the last cycle of FCR.
-
Intolerant to fludarabine is defined as discontinuation of therapy within 2 cycles due to side effects/toxicity from the last fludarabine-containing regimen.
-
ECOG score of <=1.
-
Adequate coagulation, renal, & hepatic function at Screening as follows:
- Serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 50 mL/min;
- AST & ALT <= 3.0 x ULN;
- Bilirubin <= 1.5 x ULN.
-
Gilbert's Syndrome may have a Bilirubin > 1.5 x ULN; aPTT, PT, not to exceed 1.2 x ULN.
-
Adequate bone marrow (BM) independent of any growth factor support (with the exception of subjects with BM heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows:
- ANC >= 1000/µL;
- Platelets >= 75,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening);
- Hemoglobin >= 9.0 g/dL.
-
History of autologous BM transplant must be > 6 mos post transplant (prior to the 1st dose of study drug) & have adequate BM independent of any growth factor support (with the exception of subjects with BM that is heavily infiltrated with underlying disease [80% or more] who may use growth factor support to achieve adequate BM) at Screening as follows:
- ANC >= 1500/µL;
- Platelets >= 125,000/mm3;
- Hemoglobin >= 10.0 g/dL.
-
Female subjects must be surgically sterile, postmenopausal (at least 1 year), or have negative results on a pregnancy test.
-
All female subjects not surgically sterile or postmenopausal (at least 1 year) & non-vasectomized male subjects must practice birth control.
-
History/clinically suspicious for cancer-related CNS disease.
-
Undergone allogeneic stem cell transplant.
-
Undergone autologous stem cell transplant w/i 6 mos prior to 1st dose.
-
History/predisposing condition of bleeding or currently exhibits signs of bleeding.
-
Recent history of non-chemotherapy induced thrombocytopenic associated bleeding w/i 6 mos prior to 1st dose.
-
Active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
-
Active immune thrombocytopenic purpura or history of being refractory to platelet transfusions w/i 1 yr prior to 1st dose.
-
Currently receiving/requires anticoagulation therapy or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications used to maintain the patency of a central IV catheter.
-
Significant history of cardiovascular disease, renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease.
-
Positive for HIV, Hepatitis B, or Hepatitis C.
-
Previous or current malignancies w/i the last 3 yrs:
- except adequately treated in situ carcinoma of the cervix uteri;
- basal or squamous cell carcinoma;
- in situ carcinoma of the bladder;
- or previous malignancy confined and surgically resected with curative intent.
-
Has Prolymphocytic leukemia or Richter's transformation to an aggressive B-cell malignancy.
-
Exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to uncontrolled systemic infection or diagnosis of fever and neutropenia w/i 1 week prior to study drug.
-
Prior exposure to ABT-263.
-
Received antibody therapy w/i 30 days prior to 1st dose.
-
Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, or any investigational therapy w/i 14 days prior to the 1st dose, or has not recovered to <Gr2 clinically significant AE(s) /toxicity(s) of the previous therapy.
-
Received steroid therapy for anti-neoplastic intent, w/i 7 days prior to the 1st dose with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids.
-
Received aspirin w/i 7 days prior to the 1st dose.
-
Consumed grapefruit or grapefruit products w/i 3 days prior to 1st dose.
-
Females pregnant or breast-feeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 ABT-263 -
- Primary Outcome Measures
Name Time Method Assess the safety of ABT-263 by evaluating study drug exposure, adverse events, serious adverse events, all deaths, as well as changes in laboratory determinations and vital sign parameters. monthly (at a minimum) Assess the objective response rate (partial response [PR] and confirmed complete response [CR]) of B-cell CLL subjects treated with ABT-263. Every 3 months
- Secondary Outcome Measures
Name Time Method Assess the effects of ABT-263 on duration of overall response, PFS and overall survival in subjects with B-cell CLL. Every 3 months Assess the effects of ABT-263 on time to response, 12-month survival rate, time to disease progression (TTP), and disease control rate in subjects with B-cell CLL . Every 3 months Investigate the effects of ABT-263 on quality of life (FACT-Leu and EQ-5D), ECOG performance status, and biomarkers in subject with B-cell CLL. Every 3 months